United States Food & Drug Administration
U.S. Department of Health and Human Services

The Bad Ad Program

Catherine Gray, PharmD
Acting Division Director
Division of Professional Drug Promotion
Office of Prescription Drug Promotion
Center for Drug Evaluation and Research
Food and Drug Administration
George Washington University Hospital
September 7, 2011
Objectives

1. Learn about FDA’s role in regulating prescription drug promotion and advertising, as well as the role that physicians and other healthcare professionals can play in ensuring that prescription drug promotion and advertising is truthful and not misleading.

2. Learn how to better identify misleading prescription drug promotion and advertising by reviewing specific types of violative prescription drug promotion (i.e. Overstatement of Efficacy, Minimization of Risk, Off-label Promotion).

3. Learn how to effectively report misleading prescription drug promotion to the FDA through the Bad Ad Program.
The FDA is responsible for protecting the public health by assuring the safety, efficacy, and security of human and veterinary drugs, biological products, medical devices, our nation’s food supply, cosmetics, and products that emit radiation, and by regulating the manufacture, marketing, and distribution of tobacco products.
The FDA is also responsible for advancing the public health by helping to speed innovations that make medicines and foods more effective, safer, and more affordable; and helping the public get the accurate, science-based information they need to use medicines and foods, and to reduce tobacco use to improve health.
FDA Structure

- CDER: Center for Drug Evaluation and Research
- CBER: Center for Biologics Evaluation and Research
- CDRH: Center for Devices and Radiological Health
- CFSAN: Center for Food Safety and Applied Nutrition
- CVM: Center for Veterinary Medicine
- CTP: Center for Tobacco Products
- ORA: Office of Regulatory Affairs
CDER Review (Approving) Divisions

Office of New Drugs

- Division of Cardiovascular and Renal Products
- Division of Neurology Products
- Division of Psychiatry Products
- Division of Antimicrobial Products
- Division of Botanical Products
- Division of Anesthesia and Analgesia Products
- Division of Metabolism and Endocrinology Products

- Division of Pulmonary, Allergy, and Rheumatology Products
- Division of Dermatology and Dental Products
- Division of Gastroenterology Products
- Division of Reproductive and Urologic Products
- Division of Medical Imaging Products
- Division of Nonprescription Drug Products
- Division of Oncology Products
Office of Prescription Drug Promotion (OPDP)

- To protect the public health by assuring prescription drug information is truthful, balanced and accurately communicated.

- This is accomplished through a comprehensive surveillance, enforcement and education program, and by fostering better communication of labeling and promotional information to both healthcare professionals and consumers.
What Does OPDP Regulate?

- Written and printed prescription drug promotional materials made by the company which include:
  - TV and radio commercials
  - Sales aids, journal ads, and patient brochures
  - Drug websites, e-details, webinars, Epocrates, and email alerts

- Oral Presentations made by representatives of the company which include:
  - Sales Reps
  - Hired Spokespeople
  - Medical Science Liaisons
Advertising Misconceptions

- FDA “legalized” DTC advertising in the late 1990’s
- Industry spends most of its advertising budget on DTC advertising
- FDA has the authority to ban DTC advertising
- FDA can restrict DTC advertising to certain types of products
- FDA approves ads
- FDA regulates “good taste”
Total # of promotional pieces

<table>
<thead>
<tr>
<th>Year</th>
<th>Mixed</th>
<th>Consumer</th>
<th>Professional</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>2006</td>
<td>6877</td>
<td>10901</td>
<td>43235</td>
<td>61013</td>
</tr>
<tr>
<td>2007</td>
<td>8632</td>
<td>12616</td>
<td>47040</td>
<td>68288</td>
</tr>
<tr>
<td>2008</td>
<td>6223</td>
<td>14456</td>
<td>45712</td>
<td>71085</td>
</tr>
<tr>
<td>2009</td>
<td>14970</td>
<td>15998</td>
<td>45663</td>
<td>76631</td>
</tr>
<tr>
<td>2010</td>
<td>16965</td>
<td>15930</td>
<td>45571</td>
<td>78466</td>
</tr>
<tr>
<td>2011</td>
<td>12393</td>
<td>11352</td>
<td>54094</td>
<td>6223</td>
</tr>
</tbody>
</table>
What does OPDP do?

- Advice to industry
- Advice within FDA
- Guidances and Policy Development
- Research
- **Surveillance and Enforcement**
Limitations to Surveillance

- OPDP's normal surveillance activities include:
  - Monitor drug promotions sent to us
  - Monitor medical convention exhibit halls
  - Review complaints submitted by industry competitors

- However, these surveillance activities do not allow us to monitor certain types of drug promotion that occur in places such as physician offices and industry-sponsored dinner and lunch programs. These types of promotion include:
  - Verbal statements from drug reps or company-paid speakers
  - Home-made promotional materials not submitted to FDA

That’s why we developed the Bad Ad Program
The Bad Ad Program

Created to provide HCPs an easy way to report misleading promotion that occurs in field based settings, such as offices and dinner programs.

Created by 2 former sales representatives with 11 years combined selling experience
The Bad Ad Program is an FDA-sponsored outreach program designed to educate HCPs about the role they can play in helping FDA ensure that prescription drug advertising and promotion is truthful and not misleading.

When HCPs recognize misleading drug promotion, they can help put a stop to it by reporting it to FDA:
- Call
  - 877-RX-DDMAC (877-793-3622)
- Email
  - BadAd@fda.gov
What are the most common problems with promotion?

- Omitting or downplaying of risk information
  - Example: Presenting efficacy information but no risk information

- Overstating the effectiveness
  - Example: “Drug X delivers rapid results in 3 days.” However, clinical trials for Drug X showed results at 12 weeks, not 3 days.

- Promoting unapproved uses
  - Example: Company rep tells you a drug is effective for a use that is not in the FDA approved PI

- Misleading drug comparisons
  - Example: Drug X is more effective than Drug Y, when there is not substantial evidence to support this claim
What should I do if I see misleading drug promotion?

- Any health care professional can report a potentially misleading promotion to OPDP by:
  - sending an e-mail to BadAd@fda.gov or
  - calling 877-RX-DDMAC (877-793-3622)

- Reports can be submitted anonymously by health care professionals. However, FDA encourages professionals to include contact information so that OPDP officials can follow-up if necessary for more information.
What will OPDP do with my complaint?

- Once a Bad Ad complaint is received, OPDP will evaluate it to determine if it meets the criteria needed to take an enforcement action.

- If OPDP finds the promotion to be false or misleading, we will move forward with a risk-based enforcement strategy to put a stop to the promotion ourselves, or refer it for further criminal investigation.

- If the report does not meet the required criteria at the time, it will serve as valuable information in focusing our ongoing surveillance activities.
What will happen if I report misleading promotion to OPDP?

- Contribution to ongoing OPDP surveillance activities
- Untitled letters (Notice of Violation/NOV)
- Warning letters
- Injunction/consent decree
- Seizures
- Criminal action
Examples of Enforcement Actions

- Byetta (exenatide) – Convention
- Provigil (modafinil) – P&T committee
- Savella (milnacipran HCl) – Office
- Aricept (donepezil) – TV Ad
- Derma-Smoother/FS (fluocinolone acetonide) – Website
- Vyvanse (lisdexamfetamine dimesylate) – Refrigerator magnet
Enforcement Examples: Byetta (exenatide)

- OPDP and sales rep interaction at commercial exhibit hall during 91st Endocrine Society’s Annual Meeting (ENDO)

Overstatement of Efficacy

- Sales Rep Stated:
  - “Byetta had a positive effect on cholesterol and triglyceride levels and because of this effect, ‘cardiovascular benefits’ are associated with the use of Byetta.”
Enforcement Examples: Byetta (exenatide)

Broadening of Indication/Promotion of Unapproved Use

- Sales Rep Stated:
  - “Although Byetta is not indicated for use by itself because it was not FDA approved this way and the FDA requires additional studies, Byetta can be used by itself.”
  - “There might be managed care, like Medicare or Medicaid issues when prescribing Byetta alone, but there are ways to deal with that.”
Enforcement Examples: Provigil (modafinil)

- Promotional piece distributed on behalf of company at the Maryland Health and Mental Hygiene’s P&T committee meeting in 2006.

Broadening of indication/Omission of risk

- Approved Indication:
  - To improve wakefulness in patients with excessive sleepiness associated with narcolepsy, obstructive sleep apnea/hypopnea syndrome, and shift work sleep disorder (SWSD)
Enforcement Examples: Provigil (modafinil)

Risk Information for Provigil

- **Warning:** Patients with abnormal sleepiness who take Provigil should be advised that their level of wakefulness may not return to normal. Patients with excessive sleepiness, including those taking Provigil, should be frequently reassessed for their degree of sleepiness and if appropriate, advised to avoid driving or any other potentially dangerous activity.

- **Precaution:** Patients should be cautioned about operating an automobile or other hazardous machinery until they are reasonably certain that Provigil therapy will not adversely affect their ability to engage in such activities.
The Utility of Provigil (modafinil) in the Medical and Psychiatric Population

Harry Kerasidis M.D.

Provigil (modafinil) is categorized as a stimulant medication. It is unique in its pharmacologic effect and mechanism of action.

Sleep Disorder Related Fatigue

- Sleep Disorder Related Fatigue is the sleepiness, inattentiveness, and psychological changes resulting from disordered sleep.
- Forty million Americans suffer from a chronic sleep disorder. This translates into 17% of the workforce, working in a chronically fatigued state.
- 20% of all adults report impairing sleepiness a few days a week or more. More commonly in shift workers (30%)
- Corporate America is losing $18 billion each year to lost productivity due to Sleep Disorder Fatigue.
- Nearly 1/3 of all fatal-to-the-driver heavy trucking accidents are due to driver fatigue. For every driver lost, an average of 4 innocent bystanders are also lost.

- Provigil (modafinil) has FDA indications for the following disorders that result in Sleep Disorder Fatigue:
  - Narcolepsy, a genetic disorder of primary daytime sleepiness affecting 1 of every 2500 individuals.
  - Persistent hypersomnia in treated obstructive sleep apnea. Obstructive sleep apnea affects 5% of the population. About 15% of these individuals have persistent daytime sleepiness even when the apnea is treated.
  - Shift Work Sleep Disorder, excessive sleepiness that persists in individuals engaging in shift work despite attempts to alleviate this symptom.
    - Up to 24 million Americans work irregular shift schedules.
    - Approximately 25% of night/rotating shift workers meet criteria for SWSD resulting in increased risks of motor vehicle accidents, work related accidents and errors, and clinically significant impairment in social and occupational function.
Provigil (modafinil) has utility in the treatment of other sleep disorders that cause excessive daytime sleepiness including idiopathic hypersomnia syndrome, delayed sleep phase syndrome, and, paradoxically, some cases of insomnia.

Provigil (modafinil) also has utility in the treatment of other neurologic and psychiatric disorders associated with fatigue, sleepiness, or inattentiveness:

**Multiple Sclerosis Related Fatigue**
- MS affects about 300,000 Americans. 10-20% of these individuals suffer from chronic fatigue. Provigil (modafinil) is very effective in relieving the fatigue related to MS.

**Parkinson’s Disease Related Fatigue**
- Parkinson’s and the medications used to treat Parkinson’s Disease often results in daytime sleepiness, which often can be offset with the use of Provigil (modafinil).

**Chronic Fatigue Syndrome Fibromyalgia, & chronic pain conditions**
- The fatigue related to CFS and Fibromyalgia often responds to Provigil (modafinil). Many of the medications used to treat these conditions also lead to impairing daytime sleepiness which often can be offset by Provigil (modafinil).

**Attention Deficit Disorder**
- Affects approximately 5% of the pediatric population, and 2-3% of the adult population.
- Double blind placebo controlled studies have shown significant improvements in multiple cognitive measures in this population without the risks attendant to the traditional stimulants used to treat this condition.

**Depression**
- In a retrospective case series, modafinil was found to augment actions of antidepressants, especially in patients with residual tiredness or fatigue. Clinical experience supports this published finding.

Provigil (modafinil) is a unique medication with proven efficacy, safety, utility and versatility; and low potential for abuse, dependence and diversion.
Enforcement Examples: Savella (milnacipran HCl)

- A Forest Laboratories sales rep made an sales call to a physician’s office promoting Savella in May of last year. The sales rep proactively provided the physician with information in the form of oral statements.
- A Bad Ad complaint was submitted in September.

Promotion of Unapproved Use
- “Savella is useful in back pain and mood disorder because it concurrently elevate mood and relieve depression.”
- The physician had not requested information on the drug’s use in such conditions.
Enforcement Examples: Savella (milnacipran HCl)

Unsubstantiated Superiority Claims

- “Savella has a 3:1 affinity for norepinephrine reuptake inhibition, and it is this action that makes it a better analgesic than Cymbalta.”
- “Savella is less sedating and does not result in peripheral edema and/or as much weight gain compared to Lyrica.”
- No mention of any additional risks associated with Savella use.
Enforcement Examples: Aricept (donepezil)

- OPDP sent an enforcement letter to Esai regarding two TV ads that aired in 2009.

- Let’s review some key characteristics of Aricept before we watch one of the TV ads.
Enforcement Examples: Aricept (donepezil)

Efficacy of Aricept was measured through ADAS-cog:

- Cognitive subscale of the Alzheimer’s Disease Assessment Scale measured from 0 to 70
- Multi-item instrument that examines selected aspects of cognitive performance, including elements of memory, orientation, attention, reasoning, language, and praxis.
- Higher scores indicate greater cognitive impairment
Enforcement Examples: Aricept (donepezil)

Overstatement of Efficacy

- In clinical trials, the mean differences in the ADAS-cog (0 to 70 scale) change scores compared to placebo were:
  - 5 mg/day = -2.8 units
  - 10 mg/day = -3.1 units
Enforcement Examples: Aricept (donepezil)

Overstatement of Efficacy

- The totality of the claims and presentations misleadingly overstate the efficacy of Aricept.

- These presentations imply that, as a result of Aricept treatment, patients’ cognitive and daily functioning will be restored to normal.
Enforcement Examples: Derma-Smoothe/ FS (fluocinolone acetonide)

- Warning Letter issued in December 2010 was the first enforcement resulting from a Bad Ad program complaint.

- Bad Ad complaint on the Derma-Smoothe website which:
  - Overstated efficacy
  - Omitted/Minimized risk
  - Presented Unsubstantiated Superiority claims
  - Broadened the indication
Enforcement Examples: Derma-Smoother/ FS (fluocinolone acetonide)

- **Indication:** Topical treatment of moderate to severe atopic dermatitis in pediatric patients, 3 months and older for up to 3 weeks
  - Also states to apply the least amount of Derma-Smoother to cover the affected areas, and not to apply to the diaper area, face, axillae, or groin unless directed

- **Warning:** The systemic absorption of topical corticosteroids can produce reversible hypothalamic-pituitary-adrenal (HPA) axis suppression with the potential for glucocorticosteroid insufficiency. Children may be more susceptible to systemic toxicity from equivalent doses due to their larger skin surface to body mass ratios.
Pediatric Atopic Dermatitis

Derma-Smoothe/FS®
(Body Oil)
(fluocinolone acetonide oil), 0.01%

Severe and All Over
3 mos.
and NO
Adrenal Suppression!
Pediatric Atopic Dermatitis

Derma-Smoother/FS® (Body Oil)
(fluocinolone acetonide oil), 0.01%

The only product for patients 3 months and older that can be used when their eczema is severe and all over!

Go Beyond the Itch!!

- The refined peanut oil vehicle repairs the skin barrier function by driving moisture into the skin, which is the key to treating the disease.

- The only corticosteroid that does not cause adrenal suppression, even when used over 90% of the body!

- Patient cost is only $45.00 for a full course of treatment!
Enforcement Examples: Vyvanse (lisdexamfetamine dimesylate)

- Warning Letter issued in May 2011 as a result of a Bad Ad complaint
- Refrigerator magnet
- **Indication:** Vyvanse is approved for the treatment of ADHD in children
- **Violations:** Omission of indication and risk information
Vyvanse - Titrate to achieve maximum efficacy and tolerability

Your Vyvanse sales representative is

Shire Pharmaceuticals, Inc.
725 Chesterbrook Blvd.
Wayne, PA 19087-5637 USA
Tel 800 828 2088 ext 3043
Mobile 706 340 4951
jmuse@shire.com

Jeff Muse
Senior Professional Sales Representative
ADHD Sales

Shire

The most common adverse events reported in clinical studies of Vyvanse were of appetite, insomnia, nervousness, and hostility.

Shire US Inc.
A Biotech Company™. 1-800-675-2088 www.vyvanse.com
©2008 Shire US Inc., Vayna, Pennsylvania 10917 LC01917 008A

*Vaccine

ADA 2007 Your

Request
Your Vyvanse sales representative is

Shire Pharmaceuticals, Inc.
125 Chesterbrook Blvd.
Wayne, PA 19087-5637 USA
Tel 800 828 2089 ext 3043
Mobile 706 340 4951
jmuse@shire.com

Jeff Muse
Senior Professional Sales Representative
ADHD Sales
Recognize and Report Misleading Promotion

- Phone: 877-RX-DDMAC (877-793-3622)
- E-Mail: BadAd@fda.gov
- For additional information, call OPDP’s Main Number at (301) 796-1200 or visit the website for Bad Ad: www.fda.gov/badad
- Get email updates from the Bad Ad Program.
  - Subscribe to receive information about the program and notifications of actions taken as a result of the program at: www.fda.gov/badad